Global Standards for Infant Formula Under Review: Experts Address Emerging Pathogen Threats

In a significant move to bolster the safety of one of the world’s most regulated food products, the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO) have initiated a comprehensive overhaul of international safety standards for powdered infant formula.

Following a high-level meeting of the Joint FAO/WHO Expert Meetings on Microbiological Risk Assessment (JEMRA) held in Rome this June, experts have signaled that the current Code of Hygienic Practice for Powdered Formula for Infants and Young Children (CXC 66-2008) is no longer sufficient to mitigate the evolving spectrum of microbiological hazards. The directive to modernize these standards comes as a direct response to a string of high-profile recalls and infant illnesses that have shaken public confidence in the global formula supply chain.

The Scope of the Crisis: A Shift in Pathogen Priorities

For decades, the primary concerns regarding powdered infant formula were limited to Cronobacter and Salmonella—two pathogens that are notoriously resilient in dry environments. However, recent events have forced global regulators to expand their focus.

The JEMRA committee, convened at the request of the Codex Committee on Food Hygiene (CCFH), has now officially identified botulinum neurotoxin (BoNT)-producing clostridia and Bacillus cereus (specifically the cereulide toxin) as critical threats. This expansion of priority hazards represents a significant pivot in food safety science. While Cronobacter and Salmonella remain central to risk assessments, the inclusion of spore-forming bacteria that produce potent toxins reflects a sophisticated understanding of how contamination can occur from the farm level through to the manufacturing plant.

Chronology of Recent Global Incidents

The urgency behind this regulatory review is not theoretical; it is rooted in a series of disturbing health events that have unfolded over the past 18 months.

• Early 2025 – Late 2025: The global market faced significant disruption following a series of recalls linked to Bacillus cereus. Contamination with cereulide—a heat-stable toxin that causes severe vomiting and, in some cases, liver failure—led to over 140 reported illnesses worldwide. The scale of these recalls highlighted a systemic vulnerability in the supply chain, where raw materials were tainted at the source.
• Late 2025 – Early 2026: The United States experienced back-to-back outbreaks of infant botulism linked to organic infant formulas. These incidents were particularly alarming because they involved Clostridium botulinum, a pathogen rarely associated with modern, high-tech formula production, suggesting that existing hygienic barriers were being bypassed.
• June 15–19, 2026: The FAO/WHO JEMRA meeting in Rome convened to synthesize the data from these outbreaks and provide the scientific underpinning for new Codex guidelines.
• Post-2026 Outlook: The recommendations drafted in Rome will now move through the Codex Alimentarius process, likely setting the stage for updated national regulations across member states by 2027 and beyond.

Supporting Data: Why Current Standards Are Failing

The JEMRA expert group noted that while manufacturers have become experts at controlling vegetative bacteria like Salmonella, they are less equipped to handle the physiological nature of spore-formers. Unlike vegetative cells, spores of B. cereus and C. botulinum can survive the spray-drying processes used in formula manufacturing.

The Toxin Challenge

The core issue identified by the panel is the distinction between the presence of a bacterium and the presence of its toxin. In the case of cereulide and botulinum neurotoxin, the damage is often done by the toxin itself, which can be present even if the bacteria are dormant or dead.

Furthermore, the panel highlighted that current consumer guidance—specifically regarding reconstitution temperatures—is based on the thermal death point of Cronobacter. Because B. cereus and C. botulinum spores are highly heat-resistant, standard preparation methods (such as mixing with warm water) may fail to neutralize these hazards, or worse, create an environment that encourages the germination of spores if the product is not consumed immediately.

Emerging Microorganisms

Beyond the "big four" (the two classic and two emerging pathogens), the panel recommended ongoing surveillance of:

• Enterococcus: Increasingly recognized for its role in clinical infections in NICU settings.
• Pseudomonas species: Known for their ability to form biofilms in manufacturing equipment.
• Candida species: A growing concern in the context of immunocompromised infants.

Official Responses and Regulatory Strategy

The expert group’s recommendations focus on a "farm-to-bottle" approach, emphasizing that safety cannot be "tested into" the product at the end of the line.

1. Enhanced Supplier Oversight

JEMRA has urged manufacturers to implement rigorous supplier risk management. This includes auditing dairy farms for potential sources of spore-forming bacteria, such as soil management, feed quality, and on-farm hygiene. The logic is clear: if the raw milk or whey powder is contaminated with spores, the formula manufacturer is essentially fighting a losing battle.

2. Pathogen-Specific Environmental Monitoring

The committee called for a move away from generic "indicator organism" testing. Instead, they suggest that plants must implement targeted environmental monitoring programs (EMP) that specifically look for the niches where B. cereus and clostridia thrive, such as wet spots in production areas, air filtration systems, and secondary processing equipment.

3. Revised Consumer Guidance

Perhaps the most significant impact on the average parent will be the anticipated revision of preparation instructions. Current guidelines are often contradictory, reflecting the difficulty of balancing nutritional integrity with microbiological safety. JEMRA suggests that new guidance must explicitly address the risks of toxin production, potentially changing recommendations on water temperature, storage times, and the immediate disposal of unused formula.

Implications for the Industry and Public Health

The findings from the Rome meeting serve as a "wake-up call" for the global infant formula industry. The implications are far-reaching:

For Manufacturers:
Companies will likely face increased costs as they upgrade their Hazard Analysis and Critical Control Point (HACCP) plans. The requirement for more sophisticated testing methods—such as rapid molecular diagnostics for toxin-producing genes—will necessitate investment in new laboratory infrastructure. Furthermore, the push for greater supplier transparency means that formula companies will need to exert more control over the agricultural producers they partner with, effectively turning food manufacturers into supply-chain auditors.

For Regulatory Bodies:
National agencies, such as the U.S. FDA, the European Food Safety Authority (EFSA), and the Chinese State Administration for Market Regulation, are expected to harmonize their requirements with the updated Codex standards. This alignment is vital for global trade; when standards are fragmented, it creates gaps that pathogens can exploit.

For Public Health:
The most critical implication is the potential reduction in pediatric hospitalizations. By identifying and controlling the risks associated with spore-formers, the international community aims to prevent the devastating outcomes associated with cereulide poisoning and infant botulism. However, the expert group also acknowledged a sobering "knowledge gap." They noted that surveillance data for formula-linked illnesses is still fragmented globally. Without a unified international reporting system, it remains difficult to track the true incidence of these diseases.

Conclusion: A New Era of Vigilance

The JEMRA meeting in Rome marks a turning point. For years, the industry operated under the assumption that if they could control Salmonella and Cronobacter, the product was safe. The data from 2025 and 2026 has proven that this is an incomplete safety strategy.

As the Codex Alimentarius moves to incorporate these new findings, the infant formula sector will undergo a period of intense scrutiny and technological adaptation. For parents, the message remains one of caution: while formula is a miracle of modern nutrition, its safety is a fragile equilibrium. The work being done by FAO and WHO is designed to ensure that this equilibrium is protected by the most advanced scientific oversight possible, providing a safer start for the most vulnerable among us.